ILSE gets continued support as a CARB-X Global Accelerator Partner
September 1, 2022, Union, NJ. CARB-X has announced renewed support from the U.S. Department of Health and Human Services (HHS) and Wellcome, a global charitable foundation. The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within HHS, will provide US$20 million initially and up to US$300 million over 10 years to support the existing portfolio and launch new funding rounds. Wellcome will provide US$ 70 million over three years and NIAID will provide in-kind services through access to its suite of pre-clinical services. As part of this extension CARB-X has committed to its support of ILSE being one of its four global accelerator network partner to provide scientific, technical and business support to CARB-X-funded product developers. The Global Accelerator Network is a one-of-a-kind source of know how and expertise in antibacterial drug development, diagnostics, business strategy and other areas essential to supporting CARB-X’s growing portfolio of early development research projects.